

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/094376 A1

(51) International Patent Classification⁷: **C07D 209/16**,
209/26, 213/38, C07C 259/06, C07D 403/12, A61K 31/16,
A61P 35/00

(21) International Application Number:
PCT/US2004/011990

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/463,479 17 April 2003 (17.04.2003) US
60/484,053 30 June 2003 (30.06.2003) US

(71) Applicant (for all designated States except US): **BAYER
PHARMACEUTICALS CORPORATION** [US/US];
400 Morgan Lane, West Haven, CT 06516 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Yamin**
[CN/US]; 10 Russet Road, Sandy Hook, CT 06482 (US). **DAI, Miao**
[CN/US]; 83-72 Daniels Street, Briarwood,
NY 11435 (US). **HATOUM-MOKDAD, Holia** [US/US];
43 Joseph Lane, Hamden, CT 06514 (US). **HONG, Zhen-
qiu** [CN/US]; 11A Robert Treat Drive, Milford, CT 06460
(US). **KLUENDER, Harold, C. E.** [US/US]; 27 Acad-
emy Road, Trumbull, CT 06611 (US). **LADOUCEUR,
Gaetan, H.** [CA/US]; 103 Golden Hill Drive, Guilford,
CT 06437 (US). **LI, Tindy** [US/US]; 102 Wharton Place,
West Haven, CT 06516 (US). **LOWE, Derek, B.** [US/US];
31 Bittersweet Lane, Hamden, CT 06518 (US). **MULL,
Eric, S.** [US/US]; 1937 Little Meadow Road, Guilford,
CT 06437 (US). **SHELEKHIN, Tatiana, E.** [US/US]; 4
High Valley Road, Ridgefield, CT 06877 (US). **SMITH,
Roger, A.** [US/US]; 65 Winterhill Road, Madison, CT
06443 (US). **WONG, Wai, C.** [US/US]; 10 Green Haven
Road, Trumbull, CT 06611 (US).

(74) Agents: **GREENMAN, Jeffrey, M.** et al.; Bayer Pharma-
ceuticals Corporation, 400 Morgan Lane, West Haven, CT
06516 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,
LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

[Continued on next page]

(54) Title: HYDROXAMIC ACIDS USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS



(57) Abstract: This invention relates to a compound
of Formula (I) and its use in treating hyper-proliferative
disorders.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.